Germán
Bou Arévalo
Hospital Clinic Barcelona
Barcelona, EspañaPublications in collaboration with researchers from Hospital Clinic Barcelona (43)
2024
-
Deciphering mechanisms affecting cefepime-taniborbactam in vitro activity in carbapenemase-producing Enterobacterales and carbapenem-resistant Pseudomonas spp. isolates recovered during a surveillance study in Spain
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 43, Núm. 2, pp. 279-296
2022
-
Imipenem-Relebactam Susceptibility in Enterobacterales Isolates Recovered from ICU Patients from Spain and Portugal (SUPERIOR and STEP Studies)
Microbiology spectrum, Vol. 10, Núm. 5, pp. e0292722
-
In Vitro Activity of Cefepime-Taniborbactam against Carbapenemase-Producing Enterobacterales and Pseudomonas aeruginosa Isolates Recovered in Spain
Antimicrobial Agents and Chemotherapy, Vol. 66, Núm. 3
-
In vitro activity of imipenem/relebactam against Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal (SUPERIOR and STEP studies)
The Journal of antimicrobial chemotherapy, Vol. 77, Núm. 11, pp. 3163-3172
2021
-
Distinct epidemiology and resistance mechanisms affecting ceftolozane/tazobactam in Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal depicted by WGS
The Journal of antimicrobial chemotherapy, Vol. 76, Núm. 2, pp. 370-379
2020
-
Recommendations of the Spanish Antibiogram Committee (COESANT) for selecting antimicrobial agents and concentrations for in vitro susceptibility studies using automated systems
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 38, Núm. 4, pp. 182-187
-
WGS characterization of MDR Enterobacterales with different ceftolozane/tazobactam susceptibility profiles during the SUPERIOR surveillance study in Spain
JAC-Antimicrobial Resistance, Vol. 2, Núm. 4
2019
-
Activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacterales isolates recovered from intensive care unit patients in Spain: The SUPERIOR multicentre study
International Journal of Antimicrobial Agents, Vol. 53, Núm. 5, pp. 682-688
2018
-
Activity of ceftazidime-avibactam against carbapenemase-producing Enterobacteriaceae from urine specimens obtained during the infection-carbapenem resistance evaluation surveillance trial (iCREST) in Spain
International Journal of Antimicrobial Agents, Vol. 51, Núm. 3, pp. 511-515
-
Antibiotic selection in the treatment of acute invasive infections by pseudomonas aeruginosa: Guidelines by the Spanish society of chemotherapy
Revista Espanola de Quimioterapia, Vol. 31, Núm. 1, pp. 78-100
-
Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals
Clinical Microbiology and Infection, Vol. 24, Núm. 10, pp. 1070-1076
-
Comparison of Predictors and Mortality between Bloodstream Infections Caused by ESBL-Producing Escherichia coli and ESBL-Producing Klebsiella pneumoniae
Infection Control and Hospital Epidemiology, Vol. 39, Núm. 6, pp. 660-667
-
How to: identify non-tuberculous Mycobacterium species using MALDI-TOF mass spectrometry
Clinical Microbiology and Infection, Vol. 24, Núm. 6, pp. 599-603
-
Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum β-lactamase-producing Enterobacteriaceae
International Journal of Antimicrobial Agents, Vol. 52, Núm. 5, pp. 577-585
2017
-
Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study
The Lancet Infectious Diseases, Vol. 17, Núm. 7, pp. 726-734
-
Empiric Therapy with Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Results from the INCREMENT Cohort
Clinical Infectious Diseases, Vol. 65, Núm. 10, pp. 1615-1623
-
Etestw versus broth microdilution for ceftaroline MIC determination with Staphylococcus aureus: Results from PREMIUM, a European multicentre study
Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 2, pp. 431-436
-
Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study
International Journal of Antimicrobial Agents, Vol. 50, Núm. 5, pp. 664-672
-
MIC of amoxicillin/clavulanate according to CLSI and EUCAST: Discrepancies and clinical impact in patients with bloodstream infections due to Enterobacteriaceae
Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 5, pp. 1478-1487
2016
-
A multinational, preregistered cohort study of β-lactam/β-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-β-lactamase-producing enterobacteriaceae
Antimicrobial Agents and Chemotherapy, Vol. 60, Núm. 7, pp. 4159-4169